menu
    • menu

    Company profile for Summit Therapeutics

    NEW Drugs in Dev: 4
    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    IKF/Pharmasynthese have been with fine chemicals market and APIs performance for more than 40 years.

    Virtual Booth

    Contact Supplier

    Cosma S.p.A., part of CFM Group with AMSA & Clarochem, provides global pharma & veterinary health with 300+ tons of FDA-approved APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    We’re developing new mechanism antibiotics to become the new standards of care. We have a clear strategy: through new science and philosophy, we are creating new opportunities to become the standard of care for serious infectious diseases. Our proprietary Discuva Platform is designed to uncover novel bacterial targets and develops new mechanism antibiotics against them. To date, the Discuva Platform has developed two new tar...
    We’re developing new mechanism antibiotics to become the new standards of care. We have a clear strategy: through new science and philosophy, we are creating new opportunities to become the standard of care for serious infectious diseases. Our proprietary Discuva Platform is designed to uncover novel bacterial targets and develops new mechanism antibiotics against them. To date, the Discuva Platform has developed two new targets for gonorrhoea, an ESKAPE programme and undisclosed programmes with Roche.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Summit TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    2882 Sand Hill Road Suite 106 Menlo Park CA, 94025
    Telephone
    Telephone
    +44 (0)1235 443 939
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.summitplc.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    SCOPE Summit

    SCOPE Summit

    Not Confirmed

    envelop Contact Supplier

    SCOPE Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Summit Therapeutics' Inducement Grants Under Nasdaq Listing Rule
    Summit Therapeutics' Inducement Grants Under Nasdaq Listing Rule

    30 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260130371236/en/Summit-Therapeutics-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4

    BUSINESSWIRE
    30 Jan 2026
    Share Share
    FDA Accepts BLA for Ivonescimab Combo in NSCLC Post-TKI Therapy
    FDA Accepts BLA for Ivonescimab Combo in NSCLC Post-TKI Therapy

    30 Jan 2026

    // PRESS RELEASE

    https://smmttx.com/news/press-releases/news-details/2026/Summit-Therapeutics-Announces-U-S--FDA-Acceptance-of-Biologics-License-Application-BLA-Seeking-Approval-for-Ivonescimab-in-Combination-with-Chemotherapy-in-Treatment-of-Patients-with-EGFRm-NSCLC-Post-TKI-Therapy/default.aspx

    PRESS RELEASE
    30 Jan 2026
    Share Share
    Summit Pharma's Ivonescimab (BLA) Accepted By FDA For EGFRm NSCLC
    Summit Pharma's Ivonescimab (BLA) Accepted By FDA For EGFRm NSCLC

    29 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260129109846/en/Summit-Therapeutics-Announces-U.S.-FDA-Acceptance-of-Biologics-License-Application-BLA-Seeking-Approval-for-Ivonescimab-in-Combination-with-Chemotherapy-in-Treatment-of-Patients-with-EGFRm-NSCLC-Post-TKI-Therapy

    BUSINESSWIRE
    29 Jan 2026
    Share Share
    Summit Therapeutics Reports Inducement Grants Under Nasdaq Rules
    Summit Therapeutics Reports Inducement Grants Under Nasdaq Rules

    09 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260109884241/en/Summit-Therapeutics-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4

    BUSINESSWIRE
    09 Jan 2026
    Share Share
    Summit Pharma To Present At J.P. Morgan Healthcare Conference
    Summit Pharma To Present At J.P. Morgan Healthcare Conference

    06 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260106856781/en/Summit-Therapeutics-to-Present-at-the-44th-Annual-J.P.-Morgan-Healthcare-Conference

    BUSINESSWIRE
    06 Jan 2026
    Share Share
    Summit Therapeutics Reports Inducement Grants Under Nasdaq Rules
    Summit Therapeutics Reports Inducement Grants Under Nasdaq Rules

    05 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251205119192/en/Summit-Therapeutics-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4

    BUSINESSWIRE
    05 Dec 2025
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search